




Supplemental Figure 1. **A.** Representative images of tumorsphere assay using T47D CRISPR^{cont} and CK5KO cells stably expressing ZsGreen analyzed in Figure 1B. **B.** Nuclear-GFP labeled CRISPR^{cont} and CK5KO T47D cells were seeded in phenol red-free media at 1000 cells/well in a 96 well plate in replicates of 6. Proliferation was assessed by measuring nuclear-GFP count using Incucyte Zoom. Fold change in cell count normalized to 0h timepoint is shown. Two-way ANOVA with Bonferroni post-tests were used to determine statistical significance. *** $P < 0.001$. **C.** Representative images of colony formation assays using T47D CRISPR^{cont} and CK5KO cells analyzed in Figure 1C. **D.** EV and CK5OE T47D, MCF7, and ZR75-1 cells without hormone treatment were analyzed by fluorescent immunocytochemistry for CK5 (red) and DAPI (blue). **E.** Representative images of tumorsphere assay using T47D (top) and MCF7 (bottom) EV and CK5OE cells analyzed in Figure 1E.



C




| Common cytokeratin interacting proteins identified by IP-MS | | | |
|---|------------------------|------|-------------|
| | Average Spectral Count | | |
| | CK5 | IgG | Fold Change |
| KRT5 | 40 | 23.5 | 1.7 |
| KRT18 | 35.5 | 7 | 5.1 |
| KRT8 | 30 | 14 | 2.1 |
| KRT17 | 8.5 | 1 | 8.5 |
| KRT19 | 6.5 | 0 | 6.5 |
| ITA3 | 19 | 5.5 | 3.5 |
| ITA6 | 30 | 13 | 2.3 |
| PKP3 | 10 | 5.5 | 1.8 |
| PLEC | 8.5 | 1.5 | 5.7 |




E

| Significantly differentially regulated Wnt/ β -catenin pathway genes in EWD8 cells compared to parental T47D cells | | |
|--|---|------------------------|
| Gene Symbol | Gene Name | Expression Fold Change |
| AKT3 | AKT serine/threonine kinase 3 | 6.808 |
| AXIN2 | axin 2 | 5.018 |
| CDH2 | cadherin 2 | 6.566 |
| CDH3 | cadherin 3 | 8.066 |
| CDKN2A | cyclin dependent kinase inhibitor 2A | 5.071 |
| DKK1 | dickkopf WNT signaling pathway inhibitor 1 | 6.284 |
| FZD8 | frizzled class receptor 8 | 8.04 |
| GJA1 | gap junction protein alpha 1 | 128.321 |
| KREMEN2 | kringle containing transmembrane protein 2 | 4.895 |
| MYC | v-myc avian myelocytomatosis viral oncogene homolog | 2.735 |
| PPP2R2B | protein phosphatase 2 regulatory subunit Bbeta | 55.215 |
| SOX15 | SRY-box 15 | 3.131 |
| TGFB2 | transforming growth factor beta 2 | 5.071 |
| TGFBR3 | transforming growth factor beta receptor 3 | 5.783 |
| TP53 | tumor protein p53 | 2.286 |
| WNT10A | Wnt family member 10A | 3.055 |
| WNT3A | Wnt family member 3A | 3.877 |
| WNT5A | Wnt family member 5A | 35.448 |
| WNT7A | Wnt family member 7A | 10.281 |



Supplemental Figure 2. **A.** ICC staining of CK5 (green) and DAPI (blue) shows abundant CK5 in EWD8 cells. **B.** Sequence coverage obtained for CK5 in EWD8 IP-MS experiment was generated by Scaffold. **C.** Table shows average spectral counts of keratins and desmosomal components pulled down in EWD8 IP-MS experiment. Fold change of CK5 spectral counts over IgG spectral counts are shown. **D.** Co-IP was performed in untreated EWD8 cells using a CK5 antibody and IgG negative control and was analyzed by immunoblot for CK17 expression to confirm the interaction between CK5 and CK17. **E.** Table shows Wnt/ β -catenin pathway genes that are differentially expressed in EWD8 cells compared to parental T47D cells.

A**B****C**

Supplemental Figure 3. Full blots are shown for co-IP experiments from Figure 2E for EWD8 (**A**), UCD46 (**B**), and MDA-MB-468 (**C**). Red asterisks indicate the lanes used in Figure 2E.



Supplemental Figure 4. A. β-catenin knockdown was performed in T47D-EV and CK5OE cells using 10nM siRNA for 48h. Knockdown was validated by immunoblot for β-catenin by comparing to nonsilencing siRNA transfected control (NS). Experiment was repeated twice. **B.** β-catenin knockdown was performed as described. 48h after transfection, cells were trypsinized, counted and re-plated into a tumorsphere formation assay. Tumorsphere assay was repeated 3 times, error bars represent SEM, ANOVA/Tukey was used to determine statistical significance. ** $P < 0.01$, *** $P < 0.001$. **C.** EWD8 cells were treated with 50mM LiCl for 24h, lysates were harvested, and a co-IP was performed with CK5 and IgG antibodies and analyzed by immunoblot for CK5 and β-catenin pull-down. Co-IP was repeated twice.



Supplemental Figure 5. Subcellular fractionation was performed in T47D-EV and T47D-CK5 cells. SDS-PAGE was performed with cytoplasmic (cyto), nuclear (nuc), membrane (mem), and cytoskeletal (skel) fractions and an immunoblot was performed with antibodies against alpha-tubulin (cytoplasmic control), Lamin B1 (nuclear control), E-cadherin (membrane control), and β -catenin. Membrane β -catenin was quantified using densitometry and normalizing to E-cadherin.

| ER, PR, and CK5 status in cell line and PDX models | | | | |
|--|------------|----|------------|----------------|
| | Model | ER | PR | CK5 |
| Cell Lines | T47D | + | + | – (+ with P4#) |
| | MCF7 | + | + with E2& | – (+ with P4#) |
| | ZR75-1 | + | + with E2& | – (+ with P4#) |
| | EWD8 | – | – | + |
| | MDA-MB-468 | – | – | + |
| PDX models | UCD46 | + | – | high |
| | UCD15 | + | – | low |

&E2 refers to 17 β -estradiol treatment

#P4 refers to progesterone or R5020 treatment

Supplemental Figure 6. Table outlines ER, PR, and CK5 expression in the cell lines and PDX models used in the study.